1390PDose modification and therapy interruption due to adverse events in treatment with anlotinib for refractory advanced NSCLC: Data from ALTER0303. (23rd October 2018) - Zhang, L; Si, X; Wang, H; Zhang, X; Wang, M; Han, B; Li, K; Wang, Q; Shi, J; Wang, Z; Cheng, Y; He, J; et al.